What kind of drug is anamorelin, and what is its latest status on the market?

Anamorelin is the first drug approved in Japan for the treatment of cancer cachexia. Cachexia refers to significant weight loss and loss of appetite due to malignant tumors, a state that seriously affects the patient's quality of life. Anamorelin provides an effective solution for patients with malignant tumors through a novel anabolic and antimetabolic mechanism, aiming to improve patients' living conditions and have lasting therapeutic effects, meeting patients' needs for standard care.

Anamorelin is mainly suitable for patients with a variety of malignant tumors, such as non-small cell lung cancer, gastric cancer, pancreatic cancer and colorectal cancer, especially those accompanied by weight loss and anorexia. Studies have found that the drug can help patients return to normal nutritional status by regulating appetite and promoting energy intake. In addition, the active ingredient of anamorelin is anamorelin hydrochloride, a novel oral selective ghrelin receptor agonist.

Growth hormone releasing peptide (ghrelin) is an endogenous peptide hormone secreted by the stomach in a state of hunger, with a half-life of approximately 30 minutes. When ghrelin binds to its receptor, it activates multiple pathways related to body weight, lean body mass, appetite and metabolism. Studies have shown that ghrelin levels are commonly elevated in wasted patients with different types of cancer. Exogenous ghrelin treatment in these patients has been shown to increase appetite, increase energy intake, and reduce energy expenditure, thereby improving energy balance and ultimately achieving an increase in lean body mass and retention of adipose tissue.

Compared with intravenous ghrelin, the oral form of anamorelin is not only convenient to use, but also has a longer half-life, making it more advantageous in clinical applications. Currently, anamorelin is only approved in Japan and has not yet been launched in the Chinese market. In Japan, the price of Anamorelin is approximately RMB 4,000 per box of 50mg*100 tablets of the original drug. In addition, there are also affordable imitation versions on the Laos market, with the same specifications priced at more than 2,000 yuan. If patients need to purchase, please consult a professional overseas medical institution

Overall, anamorelin, as an innovative treatment, brings new hope to patients with cancer cachexia. Its remarkable efficacy and convenient use make it an important option in clinical treatment. As more research is conducted in the future, anamorelin is expected to be more widely used around the world and help more patients improve their quality of life.

References:

https://www.helsinn.com/products/adlumiz/